Celgene (CELG)

93.19 -0.28 (0.30%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (7/25/19 *Est.)
- M&A (9/30/19 *Est)

Latest Headlines

Spark Therapeutics (ONCE) Trades Lower in Sympathy with Celgene (CELG) June 24, 2019 10:35 AM - StreetInsider Pre-Open Movers 06/24: (PCMI) (NERV) (PTN) (DFRG) (CZR) (ERI) (BMY) (CELG) (SPOT) (more) June 24, 2019 8:57 AM - StreetInsider Bristol-Myers Squibb (BMY) is Planning Divestiture of OTEZLA to Get FTC Clearance for Celgene (CELG) Deal June 24, 2019 7:02 AM - StreetInsider Bristol-Myers Squibb Provides Update on Pending Merger with Celgene June 24, 2019 6:59 AM - BizWire Mirati Therapeutics (MRTX) PT Raised to $120 at Oppenheimer June 18, 2019 6:40 AM - StreetInsider Form 4 CELGENE CORP /DE/ For: Jun 13 Filed by: Friedman Michael A June 17, 2019 4:01 PM - SEC Filing Form 4 CELGENE CORP /DE/ For: Jun 13 Filed by: CASEY MICHAEL D June 17, 2019 4:01 PM - SEC Filing Form 4 CELGENE CORP /DE/ For: Jun 13 Filed by: MARIO ERNEST June 17, 2019 4:01 PM - SEC Filing Form 4 CELGENE CORP /DE/ For: Jun 15 Filed by: BARKER RICHARD W June 17, 2019 4:01 PM - SEC Filing Form 4 CELGENE CORP /DE/ For: Jun 13 Filed by: LOUGHLIN JAMES J June 17, 2019 4:01 PM - SEC Filing Form 4 CELGENE CORP /DE/ For: Jun 13 Filed by: BONNEY MICHAEL W June 17, 2019 4:01 PM - SEC Filing Form 4 CELGENE CORP /DE/ For: Jun 13 Filed by: Haller Julia A June 17, 2019 4:00 PM - SEC Filing Bristol-Myers Squibb Co. (BMY) Estimate Raised At Cowen June 17, 2019 7:19 AM - StreetInsider BeiGene (BGNE) Regains Full Global Rights to Tislelizumab from Celgene (CELG) June 17, 2019 7:02 AM - StreetInsider Leoplus USA Wins Lyfebulb-Celgene 2019 "Addressing Unmet Needs in MS: An Innovation Challenge" June 14, 2019 9:00 AM - PR NewsWire GT Biopharma Company Update June 10, 2019 7:30 AM - PR NewsWire Celgene (CELG) Announces FDA and EMA Accept Applications for Ozanimod for Treatment of Relapsing Forms of MS June 6, 2019 7:31 AM - StreetInsider US FDA and EMA Accept Applications for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis June 6, 2019 7:30 AM - BizWire Form 4 CELGENE CORP /DE/ For: Jun 03 Filed by: WEILAND JOHN H June 5, 2019 4:07 PM - SEC Filing Form 4 CELGENE CORP /DE/ For: Jun 03 Filed by: BARKER RICHARD W June 5, 2019 4:07 PM - SEC Filing Form 4 CELGENE CORP /DE/ For: Jun 03 Filed by: LOUGHLIN JAMES J June 5, 2019 4:07 PM - SEC Filing Form 4 CELGENE CORP /DE/ For: Jun 03 Filed by: Friedman Michael A June 5, 2019 4:07 PM - SEC Filing Form 4 CELGENE CORP /DE/ For: Jun 03 Filed by: BONNEY MICHAEL W June 5, 2019 4:07 PM - SEC Filing Form 4 CELGENE CORP /DE/ For: Jun 03 Filed by: Bishop Hans Edgar June 5, 2019 4:07 PM - SEC Filing Form 4 CELGENE CORP /DE/ For: Jun 03 Filed by: COX CARRIE SMITH June 5, 2019 4:07 PM - SEC Filing Form 4 CELGENE CORP /DE/ For: Jun 03 Filed by: MARIO ERNEST June 5, 2019 4:06 PM - SEC Filing Form 4 CELGENE CORP /DE/ For: Jun 03 Filed by: CASEY MICHAEL D June 5, 2019 4:06 PM - SEC Filing Form 4 CELGENE CORP /DE/ For: Jun 03 Filed by: Haller Julia A June 5, 2019 4:06 PM - SEC Filing Form 4 CELGENE CORP /DE/ For: Jun 03 Filed by: Hall Patricia Hemingway June 5, 2019 4:06 PM - SEC Filing Bristol-Myers Squibb (BMY) Announces Leadership Team Upon Completion of Pending Merger with Celgene (CELG) June 5, 2019 7:02 AM - StreetInsider Bristol-Myers Squibb Announces Post-Closing Leadership Team June 5, 2019 6:59 AM - BizWire Celgene (CELG) Announces Data from Ongoing Studies of Liso-Cel in Patients with Difficult-to-Treat Blood Cancers at ASCO June 4, 2019 11:01 AM - StreetInsider Celgene Announces Data from Ongoing Studies of Liso-Cel in Patients with Difficult-to-Treat Blood Cancers at ASCO 2019 June 4, 2019 11:00 AM - BizWire Celgene (CELG), Acceleron Pharma (XLRN) Announce FDA Accepts Luspatercept BLA in Myelodysplastic Syndromes and Beta-Thalassemia June 4, 2019 7:32 AM - StreetInsider Celgene Corporation and Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Syndromes and Beta-Thalassemia June 4, 2019 7:30 AM - BizWire Celgene (CELG) Updated Analysis of JAKARTA2 Fedratinib Study Shows Clinically Meaningful Responses in Patients Previously Treated for Myelofibrosis with Ruxolitinib June 3, 2019 9:12 AM - StreetInsider Celgene Updated Analysis of JAKARTA2 Fedratinib Study Shows Clinically Meaningful Responses in Patients Previously Treated for Myelofibrosis with Ruxolitinib June 3, 2019 9:00 AM - BizWire Celgene (CELG) Announces Data from a Phase 1/2 Clinical Study of Iberdomide (CC-220) in Combination with Dexamethasone at ASCO 2019 Meetings June 3, 2019 5:54 AM - StreetInsider Celgene Presents Data from a Phase 1/2 Clinical Study of Iberdomide in Combination with Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma at ASCO 2019 June 2, 2019 12:45 PM - BizWire Celgene (CELG) Announces FDA Approval for REVLIMID in Combination With Rituximab For Treatment of Adults with Previously Treated FL or MZL May 28, 2019 12:32 PM - StreetInsider FDA Approves REVLIMID® (Lenalidomide) In Combination With Rituximab For the Treatment of Adult Patients with Previously Treated Follicular Lymphoma or Marginal Zone Lymphoma May 28, 2019 12:31 PM - BizWire Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes May 24, 2019 6:59 AM - BizWire Celgene (CELG) call put ratio 3.3 calls to 1 put into ASCO May 23, 2019 10:59 AM - StreetInsider Celgene and the Multiple Sclerosis Association of America Team Up to Launch MS MindShift for Awareness of Multiple Sclerosis and Brain Health May 21, 2019 8:00 AM - BizWire Jerome Zeldis, M.D., Ph.D, Former Chief Medical Officer of Celgene, to Join BioSig Board of Directors - Corrected Version May 21, 2019 7:54 AM - StreetInsider Jerome Zeldis, M.D., Ph.D, Former Chief Medical Officer of Celgene, to Join BioSig Board of Directors - Corrected Version May 21, 2019 7:52 AM - Globe NewsWire Dr. Jerome Zeldis, M.D., Ph.D, Former Chief Medical Officer of Celgene, to Join BioSig Board of Directors May 20, 2019 7:54 AM - StreetInsider Dr. Jerome Zeldis, M.D., Ph.D, Former Chief Medical Officer of Celgene, to Join BioSig Board of Directors May 20, 2019 7:52 AM - Globe NewsWire Celgene (CELG) Receives EC Approvals for REVLIMID and IMNOVID-based Triplet Combination Regimens for Patients with Multiple Myeloma May 16, 2019 8:33 AM - StreetInsider Celgene Receives European Commission Approvals for REVLIMID® (lenalidomide) and IMNOVID® (pomalidomide)-based Triplet Combination Regimens for Patients with Multiple Myeloma May 16, 2019 8:30 AM - BizWire Third Point's 13F shows new stakes in Boston Scientific (BSX), Celgene (CELG), NetFlix (NFLX) (more...) May 15, 2019 5:17 PM - StreetInsider Celgene to Highlight New and Updated Hematology and Oncology Clinical Data at Upcoming American Society of Clinical Oncology (ASCO) 2019 Annual Meeting May 15, 2019 5:04 PM - BizWire Baupost's 13F shows new stakes in Bristol-Myers Squibb (BMY), Celgene (CELG), increase in eBay (EBAY), CBS (CBS) (more...) May 15, 2019 4:57 PM - StreetInsider Corvex Management Enters Amazon (AMZN), Comcast (CMCSA) Disney (DIS), Raises MGM (MGM) (more...) 13F May 15, 2019 4:11 PM - StreetInsider Celgene (CELG) Announces POMALYST Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma May 13, 2019 7:32 AM - StreetInsider Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma May 13, 2019 7:30 AM - BizWire Enzo Biochem (ENZ) Issued U.S. Patent for Treatment of Liver Cancer Using Ozanimod May 10, 2019 10:49 AM - StreetInsider Enzo Biochem Inc. Announces Issuance of United States Patent for Treatment of Liver Cancer Using Ozanimod May 10, 2019 10:48 AM - BizWire Lyfebulb and Celgene Announce Finalists for 2019 "Addressing Unmet Needs in MS: An Innovation Challenge" May 10, 2019 7:30 AM - PR NewsWire Bristol-Myers Squibb (BMY) to sell $19 billion of bonds to fund Celgene (CELG) deal - Bloomberg May 7, 2019 1:20 PM - StreetInsider Celgene (CELG) Analysis Showed Oral Ozanimod Reduced Brain Volume Loss Across All Age Subgroups in Adults with Relapsing MS May 7, 2019 7:41 AM - StreetInsider Analysis Showed Oral Ozanimod Reduced Brain Volume Loss Across All Age Subgroups in Adults with Relapsing Multiple Sclerosis May 7, 2019 7:30 AM - BizWire Form 4 CELGENE CORP /DE/ For: May 02 Filed by: VESSEY RUPERT May 6, 2019 4:08 PM - SEC Filing Form 4 CELGENE CORP /DE/ For: May 02 Filed by: Alles Mark J May 6, 2019 4:08 PM - SEC Filing Form 4 CELGENE CORP /DE/ For: May 02 Filed by: Curran Terrie May 6, 2019 4:08 PM - SEC Filing Form 4 CELGENE CORP /DE/ For: May 02 Filed by: Biller Jonathan May 6, 2019 4:08 PM - SEC Filing Form 4 CELGENE CORP /DE/ For: May 02 Filed by: AHMED NADIM May 6, 2019 4:07 PM - SEC Filing Biotech Stocks - U.S. Holds On With Largest Medical Device Market Estimated at over $150 Billion May 6, 2019 9:00 AM - StreetInsider JPMorgan Reinstates Bristol-Myers Squibb Co. (BMY) at Overweight May 3, 2019 6:45 AM - StreetInsider Barclays Downgrades Celgene (CELG) to Equalweight May 3, 2019 4:41 AM - StreetInsider Celgene (CELG) May 95 calls active into EPS and outlook May 2, 2019 10:46 AM - StreetInsider Celgene (CELG) option implied volatility low into EPS and expected buyout closing May 2, 2019 5:09 AM - StreetInsider Bristol-Myers Squibb Company Announces Results of Early Participation in Exchange Offers and Consent Solicitations for Celgene Corporation Notes May 1, 2019 9:06 PM - BizWire Celgene (CELG), bluebird bio Inc. (BLUE) Report Publication of Results from Ongoing Multicenter Phase 1 Study of bb2121 anti-BCMA CAR T Cell Therapy in Patients with Multiple Myeloma May 1, 2019 5:27 PM - StreetInsider Celgene Corporation and bluebird bio Announce Results from Ongoing Multicenter Phase 1 Study of bb2121 anti-BCMA CAR T Cell Therapy in Patients with Multiple Myeloma Published in New England Journal o May 1, 2019 5:01 PM - BizWire Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Marketing Authorization Application to the European Medicines Agency (EMA) for MDS and Beta-Thalassemia April 26, 2019 7:30 AM - BizWire Celgene (CELG) Tops Q1 EPS by 12c, Guides FY EPS In-Line April 25, 2019 5:11 PM - StreetInsider Form 10-Q CELGENE CORP /DE/ For: Mar 31 April 25, 2019 5:11 PM - SEC Filing Form 8-K CELGENE CORP /DE/ For: Apr 25 April 25, 2019 4:54 PM - SEC Filing Celgene Reports First Quarter 2019 Operating and Financial Results April 25, 2019 4:30 PM - BizWire U.S. Proposes Increased Payments for Car-T Cancer Treatments - Bloomberg April 23, 2019 4:23 PM - StreetInsider Bristol-Myers Squibb Company Announces Commencement of Exchange Offers and Consent Solicitations for Celgene Notes April 17, 2019 8:18 AM - BizWire Stocks with Implied Volatility Movement April 17, 2019 4:50 AM - StreetInsider Form 425 CELGENE CORP /DE/ Filed by: BRISTOL MYERS SQUIBB CO April 12, 2019 5:26 PM - SEC Filing Form 8-K CELGENE CORP /DE/ For: Apr 12 April 12, 2019 4:10 PM - SEC Filing Form 425 CELGENE CORP /DE/ Filed by: CELGENE CORP /DE/ April 12, 2019 4:08 PM - SEC Filing Bristol-Myers Squibb Shareholders Approve Celgene Acquisition April 12, 2019 10:48 AM - BizWire Celgene (CELG) Stockholders Approve Acquisition by Bristol-Myers Squibb (BMY) April 12, 2019 10:34 AM - StreetInsider Celgene Stockholders Approve Proposed Acquisition by Bristol-Myers Squibb April 12, 2019 10:33 AM - BizWire Celgene (CELG) call put ratio 2.5 calls to 1 put into Bristol-Myers Squibb (BMY) Wins Shareholder Vote on Celgene Takeover April 12, 2019 10:25 AM - StreetInsider Bristol-Myers Squibb (BMY) Wins Shareholder Vote on Celgene (CELG) Takeover - Bloomberg April 12, 2019 10:23 AM - StreetInsider Bristol-Myers Squibb (BMY) is Said to be Poised to Win Celgene (CELG) Deal Vote - Bloomberg April 12, 2019 8:42 AM - StreetInsider Stocks with Implied Volatility Movement April 11, 2019 4:59 AM - StreetInsider Antengene Corporation Announces Establishment of U.S. Subsidiary and Collaboration with the Baruch S. Blumberg Institute April 8, 2019 8:00 AM - PR NewsWire Celgene (CELG), Acceleron Pharma (XLRN) Announce Submission of Luspatercept BLA to U.S. FDA April 5, 2019 9:28 AM - StreetInsider Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Biologics License Application to U.S. FDA April 5, 2019 9:28 AM - BizWire Cantor Fitzgerald Downgrades Celgene (CELG) to Neutral April 5, 2019 6:04 AM - StreetInsider Form 425 CELGENE CORP /DE/ Filed by: BRISTOL MYERS SQUIBB CO April 4, 2019 4:24 PM - SEC Filing Form 8-K CELGENE CORP /DE/ For: Apr 04 April 4, 2019 4:16 PM - SEC Filing Form 425 CELGENE CORP /DE/ Filed by: CELGENE CORP /DE/ April 4, 2019 4:15 PM - SEC Filing Bernstein Downgrades Celgene (CELG) to Market Perform April 1, 2019 8:52 AM - StreetInsider Atlantic Equities Downgrades Celgene (CELG) to Neutral April 1, 2019 5:08 AM - StreetInsider William Blair Downgrades Celgene (CELG) to Market Perform April 1, 2019 5:07 AM - StreetInsider Celgene (CELG) option implied volatility collapses after shares rally April 1, 2019 4:53 AM - StreetInsider Stocks with Implied Volatility Movement April 1, 2019 4:38 AM - StreetInsider UBS Downgrades Celgene (CELG) to Neutral April 1, 2019 4:26 AM - StreetInsider Form 425 CELGENE CORP /DE/ Filed by: BRISTOL MYERS SQUIBB CO March 29, 2019 4:33 PM - SEC Filing Bristol-Myers Squibb Issues Statement on Celgene’s Settlement with Alvogen on Revlimid® Patent Litigation March 29, 2019 1:33 PM - BizWire Form 8-K CELGENE CORP /DE/ For: Mar 29 March 29, 2019 12:07 PM - SEC Filing Starboard to withdraw its proxy solicitation to vote against the Celgene (CELG)/Bristol-Myers (BMY) deal March 29, 2019 12:03 PM - StreetInsider Celgene (CELG) Announces Settlement of U.S. REVLIMID Patent Litigation with Alvogen March 29, 2019 12:00 PM - StreetInsider Celgene Settles U.S. REVLIMID® Patent Litigation with Alvogen March 29, 2019 12:00 PM - BizWire Celgene (CELG) option implied volatility comes in after ISS recommends in favor of Celgene deal with Bristol-Myers (BMY) March 29, 2019 11:40 AM - StreetInsider Popular stocks with increasing unusual: BMY COTY WFC CELG DISH TPR March 29, 2019 11:33 AM - StreetInsider Bristol-Myers Squibb (BMY) Confirms ISS and Glass Lewis Recommend Shareholders Vote for Proposed Merger with Celgene (CELG) March 29, 2019 11:14 AM - StreetInsider Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Bristol-Myers Squibb Shareholders Vote “FOR” Proposed Merger with Celgene March 29, 2019 11:13 AM - BizWire Celgene (CELG)/Bristol-Myers Squibb (BMY) Deal Spread Collapses to 4.1% March 29, 2019 10:19 AM - StreetInsider Glass Lewis Recommends Bristol-Myers Squibb (BMY) Holders Vote for Celgene (CELG) Deal - Bloomberg March 29, 2019 9:51 AM - StreetInsider Active options: AAPL BB MU AMD AMZN NVDA BABA TSLA CELG March 29, 2019 9:42 AM - StreetInsider Celgene (CELG) option implied volatility flat into ISS recommends in favor of Celgene deal with Bristol-Myers (BMY) March 29, 2019 9:29 AM - StreetInsider Pre-Open Stock Movers 03/29: (BOXL) (PRGS) (CELG) Higher; (SGH) (RH) (CHMA) Lower (more...) March 29, 2019 9:27 AM - StreetInsider ISS Recommends Shareholders Vote 'FOR' Bristol-Myers Squibb (BMY)/Celgene (CELG) Deal March 29, 2019 9:17 AM - StreetInsider ISS Recommends Bristol-Myers Squibb (BMY) Holders Vote for Celgene (CELG) Deal - CNBC March 29, 2019 9:10 AM - StreetInsider Celgene (CELG) Shares Spike 6% March 29, 2019 9:02 AM - StreetInsider Celgene (CELG) Receives CHMP Positive Opinions for Both REVLIMID and IMNOVID -Based Triplet Combination Regimens for Patients with MM March 29, 2019 8:13 AM - StreetInsider Celgene Receives CHMP Positive Opinions for Both REVLIMID® (lenalidomide) and IMNOVID® (pomalidomide)-Based Triplet Combination Regimens for Patients with Multiple Myeloma March 29, 2019 8:12 AM - BizWire Celgene (CELG) Drifts to Low, Down 2.5% March 28, 2019 3:04 PM - StreetInsider Bristol-Myers Squibb (BMY) April calls active into ISS expected to weigh in on Celgene deal soon March 27, 2019 10:31 AM - StreetInsider Celgene (CELG) April puts active into ISS expected to weigh in on the Bristol-Myers Squibb (BMY)/Celgene (CELG) deal March 27, 2019 10:27 AM - StreetInsider ISS Seen Weighing in on Celgene (CELG)/Bristol-Myers Squibb (BMY) Deal on Monday - Faber March 27, 2019 10:08 AM - StreetInsider Full Article List